DIA 2016 Editor’s Take – SynteractHCR

Thought Leader:

Dr. Martine Dehlinger-Kremer, Global VP and Regulatory Affairs, SynteractHCR

July 27, 2016      

Dr. Martine Dehlinger-Kremer of SynteractHCR discusses the advantages of the new EU clinical trial regulation intended to streamline the clinical trial approval process by simplifying the authorization process, which is set to come into force at the end of 2017, and its relevance to U.S. companies and the impact on the industry as a whole.

For more information please visit www.synteracthcr.com.

Post a Comment

You must be logged in to post a Comment.

FEEDBACK